首页|脑膜瘤的临床治疗进展

脑膜瘤的临床治疗进展

Clinical treatment progress of meningiomas

扫码查看
脑膜瘤是中枢神经系统常见的原发性肿瘤.根据世界卫生组织(WHO)2016年组织学标准,大多数脑膜瘤为良性(WHO分级Ⅰ级),5%~7%为非典型脑膜瘤,3%为间变性脑膜瘤.目前,脑膜瘤主要采用随访观察和手术治疗;对非典型和间变性脑膜瘤,可辅助放化疗;颅底脑膜瘤常涉及血管神经结构,手术难度大;复发性肿瘤以放疗和再次手术为主.基于NF2、SMO、TERT、TRAF7等基因突变和甲基化谱的肿瘤分子特征的靶向治疗有道进一步研究.本文根据国际指南和最近的文献介绍当前的标准治疗方法,并描述了为治疗复杂脑膜瘤而开展的新技术.
Meningiomas are common primary tumors in the central nervous system. According to the histological criteria of the World Health Organization (WHO) in 2016,the majority of meningiomas are benign (WHO grade Ⅰ),5%~7% are atypical meningiomas,and 3% are anaplastic meningiomas. Currently,meningiomas are mainly treated with follow-up observation and surgical treatment;for atypical and anaplastic meningiomas,adjuvant radiotherapy and chemotherapy can be applied;skull base meningiomas often involve vascular and neural structures,resulting in high surgical difficulty;recurrent tumors are mainly treated with radiotherapy and reoperation. Targeted therapy based on tumor molecular characteristics such as gene mutations of NF2,SMO,TERT,TRAF7 and methylation profiles is under further investigation. This article introduces the current standard treatment methods based on international guidelines and the latest literature,and describes the new technologies developed for the treatment of complex meningiomas.

MeningiomaMolecular characteristicsSurgical treatmentTargeted therapy

李燃、张万增、赵庚水

展开 >

053000 河北衡水,哈励逊国际和平医院神经外科

脑膜瘤 分子特征 手术治疗 靶向治疗

2024

中国临床神经外科杂志
广州军区武汉总医院

中国临床神经外科杂志

CSTPCD
影响因子:0.781
ISSN:1009-153X
年,卷(期):2024.29(7)